Skip to content
MarketScale
‹ Back to IndustriesHealthcare

It’ll Take a Village to Deliver the Innovative, Less Invasive, Affordable Solutions to the Healthcare Market with Raja Abid

There’s no getting around the fact that the healthcare industry needs solutions to help solve its myriad challenges. A holistic approach to healthcare solutions is a pathway Raja Abid, Healthcare Economic Leader at Boston Scientific, believes can deliver innovative, less invasive, and affordable solutions to the healthcare market. Abid kicked off his career in med…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

There’s no getting around the fact that the healthcare industry needs solutions to help solve its myriad challenges. A holistic approach to healthcare solutions is a pathway Raja Abid, Healthcare Economic Leader at Boston Scientific, believes can deliver innovative, less invasive, and affordable solutions to the healthcare market.

Abid kicked off his career in med school. He discovered there were so many facets to healthcare he wanted to learn different sides of the market. Abid got his MBA in healthcare administration, which opened his eyes to the many possibilities for him to make a difference. Keeping an open mind is a trait Abid values, and it’s what guided him through his career and led him to Boston Scientific.

All areas within healthcare offer tremendous value and opportunities to create solutions, but the siloing that often accompanies these areas must dissipate to allow for better communication. “The only way you’re going to improve quality, value, and delivery of care, is when everybody starts talking to each other, builds care pathways that make sense, efficient, and highly effective,” Abid said. Still, Abid believes the next ten years in healthcare will focus on solving this challenge.

In Abid’s role with Boston Scientific, he provides economic support data, so healthcare organizations understand the financial impact of the devices they purchase. A device may seem like a significant spend, but long-term financial benefits and positive patient results generated from that device could be tremendous.

Seeing healthcare from the side of a device manufacturer, Abid knows that solutions come from partnerships. “Medical device companies come up with new products and technologies. We educate the physicians and the patients on their options because, as you can imagine, most patients go to a physician, and a physician’s going to do what they’ve been doing for the last fifteen to twenty years.” Educating the healthcare community on the latest innovations can make all the difference.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512